These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37558921)

  • 1. A need for clinical trial: re-purposing the Monoamine Oxidase Inhibitors (MAO-I) for rheumatoid arthritis (RA).
    Bala A
    Inflammopharmacology; 2023 Dec; 31(6):3367-3370. PubMed ID: 37558921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.
    Duarte P; Cuadrado A; León R
    Handb Exp Pharmacol; 2021; 264():229-259. PubMed ID: 32852645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future.
    Tan YY; Jenner P; Chen SD
    J Parkinsons Dis; 2022; 12(2):477-493. PubMed ID: 34957948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A second life for MAO inhibitors? From CNS diseases to anticancer therapy.
    Sblano S; Boccarelli A; Mesiti F; Purgatorio R; de Candia M; Catto M; Altomare CD
    Eur J Med Chem; 2024 Mar; 267():116180. PubMed ID: 38290352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical applications of MAO-inhibitors.
    Riederer P; Lachenmayer L; Laux G
    Curr Med Chem; 2004 Aug; 11(15):2033-43. PubMed ID: 15279566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials.
    Yan R; Cai H; Cui Y; Su D; Cai G; Lin F; Feng T
    Eur J Neurol; 2023 Apr; 30(4):1118-1134. PubMed ID: 36437702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic, Molecular and Computational Aspects of Novel Monoamine Oxidase (MAO) Inhibitors.
    Ramesh M; Dokurugu YM; Thompson MD; Soliman ME
    Comb Chem High Throughput Screen; 2017; 20(6):492-509. PubMed ID: 28294055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.
    Schapira AH
    CNS Drugs; 2011 Dec; 25(12):1061-71. PubMed ID: 22133327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Monoamine oxidase as a target for drug action].
    Drozak J; Kozłowski M
    Postepy Hig Med Dosw (Online); 2006; 60():498-515. PubMed ID: 17060892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity.
    Bartl J; Müller T; Grünblatt E; Gerlach M; Riederer P
    J Neural Transm (Vienna); 2014 Apr; 121(4):379-83. PubMed ID: 24272680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into the Mechanism of the Therapeutic Potential of Herbal Monoamine Oxidase Inhibitors in Neurological Diseases.
    Mannan A; Singh TG; Singh V; Garg N; Kaur A; Singh M
    Curr Drug Targets; 2022; 23(3):286-310. PubMed ID: 34238153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoamine oxidase inactivation: from pathophysiology to therapeutics.
    Bortolato M; Chen K; Shih JC
    Adv Drug Deliv Rev; 2008; 60(13-14):1527-33. PubMed ID: 18652859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposing monoamine oxidase inhibitors (MAOI) for the treatment of rheumatoid arthritis possibly through modulating reactive oxidative stress mediated inflammatory cytokines.
    Sur D; Dutta A; Mondal C; Banerjee A; Haldar PK; Maji HS; Bala A
    Inflammopharmacology; 2022 Apr; 30(2):453-463. PubMed ID: 35266068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review.
    Manzoor S; Hoda N
    Eur J Med Chem; 2020 Nov; 206():112787. PubMed ID: 32942081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzyloxynitrostyrene analogues - A novel class of selective and highly potent inhibitors of monoamine oxidase B.
    Van der Walt MM; Terre'Blanche G; Petzer JP; Petzer A
    Eur J Med Chem; 2017 Jan; 125():1193-1199. PubMed ID: 27855360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An updated patent review on monoamine oxidase (MAO) inhibitors.
    Guglielmi P; Carradori S; D'Agostino I; Campestre C; Petzer JP
    Expert Opin Ther Pat; 2022 Aug; 32(8):849-883. PubMed ID: 35638744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting peripheral and central MAO-B ameliorates joint inflammation and cognitive impairment in rheumatoid arthritis.
    Won W; Choi HJ; Yoo JY; Kim D; Kim TY; Ju Y; Park KD; Lee H; Jung SY; Lee CJ
    Exp Mol Med; 2022 Aug; 54(8):1188-1200. PubMed ID: 35982301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects.
    Riederer P; Müller T
    J Neural Transm (Vienna); 2018 Nov; 125(11):1751-1757. PubMed ID: 29569037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coumarin derivatives as inhibitors of d-amino acid oxidase and monoamine oxidase.
    Bester E; Petzer A; Petzer JP
    Bioorg Chem; 2022 Jun; 123():105791. PubMed ID: 35413582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.
    Bainbridge JL; Page RL; Ruscin JM
    Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.